Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Non-clear Cell Renal Cell Carcinoma”

235 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 235 results

Early research (Phase 1)Looking for participantsNCT05176483
What this trial is testing

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

Who this might be right for
Renal Cell Carcinoma (RCC)Metastatic Castration-Resistant Prostate Cancer (mCRPC)Urothelial Carcinoma (UC)+7 more
Exelixis 1,314
Testing effectiveness (Phase 2)Study completedNCT03685448
What this trial is testing

ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)

Who this might be right for
Renal Cell CarcinomaPapillary Renal Cell Carcinoma Type 1Papillary Renal Cell Carcinoma Type 2+3 more
Australian and New Zealand Urogenital and Prostate Cancer Trials Group 35
Testing effectiveness (Phase 2)UnknownNCT04958473
What this trial is testing

Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer

Who this might be right for
Renal Cell CarcinomaClear Cell Renal Cell Carcinoma
Tianjin Medical University Second Hospital 40
Not applicableStudy completedNCT03419572
What this trial is testing

Non-interventional Study of Cabozantinib in Adults With Advanced Renal Cell Carcinoma

Who this might be right for
Renal Cell Carcinoma
Ipsen 689
Not applicableApproved For MarketingNCT04100694
What this trial is testing

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

Who this might be right for
NRG1 FusionPancreatic CancerNon Small Cell Lung Cancer+8 more
Merus B.V.
Testing effectiveness (Phase 2)Ended earlyNCT03637803
What this trial is testing

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

Who this might be right for
OncologySolid TumorNon Small Cell Lung Cancer+3 more
4D pharma plc 63
Early research (Phase 1)Active Not RecruitingNCT05239143
What this trial is testing

P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors

Who this might be right for
Breast CancerOvarian CancerNon Small Cell Lung Cancer+6 more
Poseida Therapeutics, Inc. 180
Early research (Phase 1)Looking for participantsNCT07195916
What this trial is testing

Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

Who this might be right for
Solid TumorsHematologic Malignancies
Incyte Corporation 280
Testing effectiveness (Phase 2)UnknownNCT05220267
What this trial is testing

Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma

Who this might be right for
Non Clear Cell Renal Carcinoma
Sun Yat-sen University 43
Testing effectiveness (Phase 2)Looking for participantsNCT05363280
What this trial is testing

Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment

Who this might be right for
Small Cell Lung CancerRenal Cell Carcinoma (RCC)Non-Small Cell Lung
Advenchen Pharmaceuticals, LLC. 80
Testing effectiveness (Phase 2)Looking for participantsNCT03093688
What this trial is testing

Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor

Who this might be right for
Non-small Cell Lung CancerSmall Cell Lung CancerPancreas Cancer+3 more
Shanghai Public Health Clinical Center 40
Early research (Phase 1)Study completedNCT04504669
What this trial is testing

First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

Who this might be right for
Clear Cell Renal Cell CancerNon-Small-Cell Lung CancerTriple Negative Breast Neoplasms+6 more
AstraZeneca 60
Early research (Phase 1)Study completedNCT00944905
What this trial is testing

Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)

Who this might be right for
Renal Cell CarcinomaNon-hodgkin's Lymphoma
Bristol-Myers Squibb 46
Early research (Phase 1)Ended earlyNCT04628780
What this trial is testing

Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors

Who this might be right for
Non-small-cell Lung CancerSquamous Cell Carcinoma of the Head and NeckRenal Cell Carcinoma+3 more
Pfizer 37
Not applicableStudy completedNCT04353765
What this trial is testing

Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors

Who this might be right for
Locally Advanced or Metastatic Renal Cell Carcinoma
Ipsen 247
Testing effectiveness (Phase 2)Ended earlyNCT02771626
What this trial is testing

Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Clear Cell Renal Cell Carcinoma (ccRCC)MelanomaNon-small Cell Lung Cancer (NSCLC)
Calithera Biosciences, Inc 118
Not applicableStudy completedNCT03948724
What this trial is testing

Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology

Who this might be right for
Therapeutic Patient EducationImmune Checkpoint InhibitorsMelanoma+4 more
Institut Cancerologie de l'Ouest 411
Early research (Phase 1)Study completedNCT00827177
What this trial is testing

Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 87
Testing effectiveness (Phase 2)Active Not RecruitingNCT05879822
What this trial is testing

Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive

Who this might be right for
Advanced Solid Tumor
Incyte Corporation 73
Not applicableEnded earlyNCT04106167
What this trial is testing

Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

Who this might be right for
Advanced Solid TumorLymphomaGastric Cancer+15 more
Fate Therapeutics 20
Load More Results